Abstract 114P
Background
Lymphocyte-activation gene 3 (LAG-3) is an immune checkpoint receptor that negatively regulates T cell activation and inhibits the immune microenvironment. We explored the prognostic effect of LAG-3-positive tumor-infiltrating lymphocytes (TILs) in metastasis colorectal cancer (mCRC) and its correlation with important genomic alterations of mCRC.
Methods
A total of 139 patients with mCRC were enrolled. Tissues from both the primary tumor and distant metastasis were evaluated for LAG-3 expression by immunohistochemical (IHC) staining. LAG-3 staining of TILs in either the tumor front or tumor center were considered positive. The level of LAG-3 expression was reported as the number of LAG-3-positive immune cells in one high-power field (HPF).
Results
LAG-3 expression was evaluated in 116 primary and 98 metastatic tumor samples. The level of LAG3 expression was higher in the primary tumors compared to the metastatic tumors (median 1.35 vs. 0.55/HPF, p = 0.033). We analyzed the clinicopathologic feature in populations with different levels of LAG3 expression (LAG-3+ TIL >0 vs. =0/HPF; ≥1 vs. <1; ≥3 vs. <3; ≥5 vs. <5; ≥10 vs. <10) in primary and metastatic tumor, respectively. In patients with primary tumors of LAG-3+ TIL >0, there was higher percentage of RAS mutation [54% vs. 20%, p= 0.007]. Patients with primary tumors of LAG-3+ TIL ≥5 more frequently exhibited high tumor mutation burden (TMB ≥10 mutations/mb) tumor than those of LAG-3+ TIL <5 [18% vs. 3%, p= 0.0036]. In subgroups of primary tumors with LAG-3 expression of 3, 5 and 10 or greater, overall survival (OS) were shorter than those with LAG-3 expression less than 3, 5 and 10, respectively [median: LAG-3+ TIL ≥3 vs. <3, 30.1 vs. 45.2 months, Hazard ratio (HR) 1.687, p = 0.035; ≥5 vs. <5, 28.3 vs. 44.6 months, HR 1.791, p = 0.025; ≥10 vs. <10, 28.0 vs. 45.2 months, HR 2.137, p = 0.0073]. This difference was not observed in metastatic tumors. Notably, in metastatic tumors, OS was longer in the LAG-3 >0 than LAG-3=0 group (51.9 vs. 32.5 months, HR 0.513, p = 0.0208).
Conclusions
LAG-3 expression level in primary CRC tumor was associated with negative survival outcome and can serve as a potential prognostic marker. Further studies are needed to explore the optimal cutoff level to identify the candidates that benefit most from LAG-3 blockade.
Clinical trial identification
B-ER-110-172; 23 June 2021.
Editorial acknowledgement
Legal entity responsible for the study
National Cheng Kung University Hospital.
Funding
National Cheng Kung University Hospital.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
49P - Survival outcomes of HER2-positive breast cancer patients treated with neoadjuvant therapy at a single cancer centre in India
Presenter: Minit Shah
Session: Poster Display
Resources:
Abstract
50P - A nationwide retrospective cohort study of the response to neoadjuvant chemotherapy between HER-2 low and HER-2 negative non-metastatic breast cancer in Qatar: A real-world analysis
Presenter: Ahmed Kardousha
Session: Poster Display
Resources:
Abstract
51P - Four-year outcomes of hypofractionated postmastectomy radiation therapy of 39 Gy in 13 fractionations
Presenter: Sevinj Gahramanova
Session: Poster Display
Resources:
Abstract
52P - A comparative study to assess volumetric and dosimetric profile of heart and lung in patients undergoing left sided post mastectomy radiotherapy: Continuous positive airway pressure (CPAP) versus free breathing (FB) techniques
Presenter: Pritanjali Singh
Session: Poster Display
Resources:
Abstract
29P - HUWE1 inhibition has tumor suppressive effect in triple-negative breast cancer cell lines by modulating glycolytic and immune modulatory markers
Presenter: Shruti Kahol
Session: Poster Display
Resources:
Abstract
53P - Radiotherapy utilization rate for breast cancer in Indonesia: A call for empowering cancer care
Presenter: Donald Manuain
Session: Poster Display
Resources:
Abstract
58P - Safety and pharmacokinetics (PK) of vepdegestrant in Japanese patients with estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Results from a Japanese phase I study
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
59P - Comprehensive genomic profiling (CGP) unravels druggable targets in breast carcinoma (BC): A single institutional experience
Presenter: Gautam Balaram
Session: Poster Display
Resources:
Abstract
60P - A study of gene alterations in Asian patients with late stage and recurrent breast cancer
Presenter: Po-Sheng Yang
Session: Poster Display
Resources:
Abstract
61P - Tumor cell-released autophagosomes (TRAPs) remodel the breast tumor microenvironment by inducing the formation of inflammatory cancer-associated fibroblasts (CAFs)
Presenter: Chengdong Wu
Session: Poster Display
Resources:
Abstract